Survey benchmarks External Education trends and needs to inform structure, capabilities, strengths and gaps that can be leveraged for planning in your organization.
Last month, Medical Affairs and clinical experts from six organizations came together to help make clinical trials more accessible to and better understood by people facing vitiligo. You can do this in your therapeutic area.
In July, MAPS partnered with APPA Australia , IFAPP Academy and the Medical Science Liaison Society to produce a joint position paper on the role of Medical Science Liaisons in the pharmaceutical industry. September 1st, we hosted a discussion with some of the paper authors to discuss consensus on best practices.
In part two of that first discussion, you'll hear from more of the authors on:
Evidence is emerging to demonstrate the value of patient engagement throughout the medicine development lifecycle. Consequently, many pharmaceutical companies are adopting more patient‑centric approaches and a range of tools are available to support this. There are many case studies highlighting effective patient involvement in clinical trial design, or in the development of patient education materials – but we rarely see patient involvement in company-sponsored medical publications.
Patients have valuable and unique insights into key areas such as the lived experience, treatment journeys, and unmet needs. Their perspectives should be captured to strengthen the peer-reviewed medical literature. In this session we will highlight the opportunities for patients to become authors and review some of the tools and training available to support them. Using a recent case study, we will show how patients can and do add value as co-authors of company-sponsored publications.
As Medical Affairs' audiences and outlets expand, no single channel will suffice for all communications. Instead, the activities of functions including Medical Information, Medical Communications, and Field Medical will require multichannel or omni-channel engagement. This webinar starts with an overview of multichannel vs. omnichannel engagement before offering actionable advice for Medical Affairs teams seeking to reach external stakeholders in the new normal of hybrid, asynchronous, individualized engagement.
Attendees will understand:
HCP engagement on social media continues to grow and with it the need to proactively identify and seize new opportunities under this new engagement paradigm.
Hear from a panel of social media and medical communications experts as they discuss, with real-world examples, the evolving trends and models for pharma and biotech medical communications to effectively facilitate compliant HCPs social media engagement.
This MAPS podcast details potential areas for compliant collaboration by MSLs with Academic Drug Developers.
This webinar describes key steps and considerations for creating a successful social media presence for your Medical Affairs team. First, it is important to conduct a landscape analysis to determine how your competitors use social media and how your target audience interacts with content. It is also critical to create a project plan that defines the communications framework, editorial calendar, standard responses, and funnels for content creation. Challenges that arise during this process, such as navigating compliance considerations, may present major hurdles. Additionally, we will discuss how to assess the success of social media communications against objectives by utilizing metrics to help plan for future changes or expansion. Key medical audiences are increasingly using social media as a source for clinical information. By creating a strategic framework for the use of social media, Medical Affairs teams can leverage this emerging opportunity to increase the visibility of key data.
This webinar will:
“Data doesn’t exist until it is published.” Here, MAPS speaks with MedComm FAWG co-leads about innovations and future directions for Medical Communications within Medical Affairs.
This MAPS podcast details potential areas for compliant collaboration by MSLs with Patient Advocacy Groups.